These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 6296836

  • 1. Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes.
    North JR, Morgan AJ, Thompson JL, Epstein MA.
    Proc Natl Acad Sci U S A; 1982 Dec; 79(23):7504-8. PubMed ID: 6296836
    [Abstract] [Full Text] [Related]

  • 2. Comparative immunogenicity studies on Epstein-Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton-top tamarins.
    Morgan AJ, Epstein MA, North JR.
    J Med Virol; 1984 Dec; 13(3):281-92. PubMed ID: 6327902
    [Abstract] [Full Text] [Related]

  • 3. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo.
    Thorley-Lawson DA, Poodry CA.
    J Virol; 1982 Aug; 43(2):730-6. PubMed ID: 6287039
    [Abstract] [Full Text] [Related]

  • 4. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.
    Thorley-Lawson DA, Geilinger K.
    Proc Natl Acad Sci U S A; 1980 Sep; 77(9):5307-11. PubMed ID: 6254073
    [Abstract] [Full Text] [Related]

  • 5. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.
    Hoffman GJ, Lazarowitz SG, Hayward SD.
    Proc Natl Acad Sci U S A; 1980 May; 77(5):2979-83. PubMed ID: 6248876
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Two large virion envelope glycoproteins mediate Epstein-Barr virus binding to receptor-positive cells.
    Wells A, Koide N, Klein G.
    J Virol; 1982 Jan; 41(1):286-97. PubMed ID: 6283120
    [Abstract] [Full Text] [Related]

  • 8. Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein.
    Qualtiere LF, Chase R, Vroman B, Pearson GR.
    Proc Natl Acad Sci U S A; 1982 Jan; 79(2):616-20. PubMed ID: 6176998
    [Abstract] [Full Text] [Related]

  • 9. Vaccination against Epstein-Barr virus: current progress and future strategies.
    Epstein MA.
    Lancet; 1986 Jun 21; 1(8495):1425-7. PubMed ID: 2872525
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen.
    Strnad BC, Schuster T, Klein R, Hopkins RF, Witmer T, Neubauer RH, Rabin H.
    J Virol; 1982 Jan 21; 41(1):258-64. PubMed ID: 6177865
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Epstein-Barr (EB) virus antibodies in rheumatoid arthritis.
    Ferrell PB, Tan EM.
    Springer Semin Immunopathol; 1981 Jan 21; 4(2):181-91. PubMed ID: 6275562
    [No Abstract] [Full Text] [Related]

  • 15. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.
    Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J.
    J Exp Med; 2006 Apr 17; 203(4):995-1006. PubMed ID: 16549597
    [Abstract] [Full Text] [Related]

  • 16. Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides.
    North JR, Morgan AJ, Epstein MA.
    Int J Cancer; 1980 Aug 17; 26(2):231-40. PubMed ID: 6162806
    [Abstract] [Full Text] [Related]

  • 17. Persistence of transforming and nontransforming Epstein-Barr virus in high passages of P3HR-1 cell lines.
    Gerber P, Ablashi D, Magrath I, Armstrong G, Andersen P, Trach L.
    J Natl Cancer Inst; 1982 Sep 17; 69(3):585-90. PubMed ID: 6287082
    [Abstract] [Full Text] [Related]

  • 18. Efficient purification of Epstein-Barr virus membrane antigen gp340 by fast protein liquid chromatography.
    David EM, Morgan AJ.
    J Immunol Methods; 1988 Apr 06; 108(1-2):231-6. PubMed ID: 2832478
    [Abstract] [Full Text] [Related]

  • 19. In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340.
    Ulaeto D, Wallace L, Morgan A, Morein B, Rickinson AB.
    Eur J Immunol; 1988 Nov 06; 18(11):1689-97. PubMed ID: 2904885
    [Abstract] [Full Text] [Related]

  • 20. Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals.
    Epstein MA, Randle BJ, Finerty S, Kirkwood JK.
    Clin Exp Immunol; 1986 Mar 06; 63(3):485-90. PubMed ID: 3011324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.